News

Zydus’ Baddi manufacturing plant engaged in manufacturing oral solid dosage forms of drugs include hard gelatin capsules and tablets. Zydus Cadila chairman and managing director Pankaj Patel said

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has concluded that pioglitazone-containing medicines remain a valid treatment option for patients with type 2 diabetes. The CHMP

Based on company’s DOS47 technology, L-DOS47 is intended to function by leveraging a natural process in the body called the urea cycle to produce an anti-cancer effect. Th

The company is planning to develop some of its vaccines jointly with its partners from further financing round, which will be concluded by the end of 2011. CAP

Tarceva is a once-daily, oral, non-chemotherapy treatment for the treatment of advanced or metastatic NSCLC. The CHMP positive opinion is based on EURTAC study data that demonstrated Tarceva

As per the terms of the agreement, Bristol-Myers Squibb will take over all of Amira’s issued and outstanding shares of capital stock and stock equivalents. Bristol-Myers Squibb will

RG1068, a synthetic version of the hormone secretin, is known to both stimulate the secretion of pancreatic fluid into the pancreatic ducts and to increase blood flow to

The lawsuit covers Pronova BioPharma’s US patent no 7,732,488, US patent no. 7,678,930 and US patent no. 7,718,698. The patents entitled, ‘Pharmaceutical Composition Comprising Low Concentrations of Environmental

CHMP’s decision was backed by the positive results of a Phase III RADIANT-3 (RAD001 In Advanced Neuroendocrine Tumors) trial which demonstrated that the patients with advanced pancreatic NET